The objective of this study is to analyze the safety and efficacy of a novel device for minimally invasive mitral valve repair. Data of the early and intermediate postoperative period will be collected within routine clinical follow-up in order to assess morbidity and mortality as well as echocardiographic parameters.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary safety endpoint - 30day Mortality
Timeframe: 30 days
Primary efficacy endpoint - Implantation Time
Timeframe: intraoperative
Martin Andreas, MD, PhD, MBA